HER2 gene amplification in gastric and breast cancer are eligible for Trastuzumab therapy .
HER2 (ERBB2) is a proto-oncogene located on chromosome17 and belongs to the family of epidermal growth factor receptor (EGFR). The gene product is expressed in normal epithelial cells for cell division, proliferation, differentiation and apoptosis. Amplification and/or over-expression of this gene has been reported in up to 30% of breast cacner and in 9%-27% in gastric cancer.
The test is performed in 7 working days after the reception of the sample.